InVivo Biosystems
Wednesday, June 05, 2024
Company Presentation
CNS/Neurological
Company Presentation Theater 4
In Vivo Biosystems enables drug discovery and development in neurological, metabolic, and rare monogenic disease indications with our premiere proprietary platform, RapidGen.
RapidGen leverages -omic data and multiplexed CRISPR to speed target identification & multimodal therapeutics screening on highly relevant behavioral and molecular endpoints in vivo.
Company Website:
https://invivobiosystems.com/
Lead Product in Development:
IVB-269
Number Of Unlicensed Products (For Which You Are Seeking Partners):
2
Company HQ City
Eugene
Company HQ State
Oregon
Company HQ Country
United States
CEO/Top Company Official
Kat McCromick
Development Phase of Primary Product
Pre-Clinical
Primary Speaker
)
)
)
)
)
)
){kind=logo}
){kind=logo}
.png/fit-in/500x500/filters:no_upscale())